RAC 0.97% $1.54 race oncology ltd

Ann: H1 2023 Preclinical and Clinical Programs Update, page-68

  1. 1,527 Posts.
    lightbulb Created with Sketch. 379
    I had to "reassign" one of my GA tonight just for @pipjon but so many great contributions to the thread for this announcement.

    Re EUR CDMO time will tell, expect a lot of speculation until the July/August strategic update but for the drug development moving preparing for commercialisation phase wouldn't be surprised if there was a collaboration/partnership (these take many forms, not just lambo buyouts) of sorts being worked out that needs to be announced at the right time. What are your thoughts @Boffin99 ?

    Given the disadvantages of the standard of care central line CVC there should be a lot of interest from BP on the new formula & delivery pharmacokinetics.
    Drug development trials is an area I need to revisit as I spent more time jumping ahead to the marketing modules instead.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.